- Yale EndocrinologyDana Clinic Building789 Howard Avenue, Fl 2ndNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
Kevan Herold, MD
Biography
Kevan Herold, MD, is an endocrinologist who treats adult and child patients with type 1 and type 2 diabetes, diabetes that occurs after therapies for cancer, and hypoglycemia (low blood glucose levels).
Type 1 diabetes is an autoimmune disease that is often diagnosed in children and teens. The immune system mistakenly attacks healthy body tissues and destroys cells in the pancreas that produce insulin.
Dr. Herold’s goal is to better understand the mechanisms for type 1 diabetes in order to develop new treatments for his patients. His research revolves around beta cell function. In type 1 diabetes, beta cells produce little or no insulin and are destroyed by T cells from the immune system. Dr. Herold and his lab also research autoimmune diabetes development in cancer patients.
Recently, Dr. Herold was the principal investigator for a clinical trial that showed the effectiveness of teplizumab, a new drug that could delay type 1 diabetes development by two years. He is chair of NIDDK (National Institute of Diabetes and Digestive Diseases) TrialNet, an international network of type 1 diabetes researchers.
Dr. Herold is C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine.
Titles
- C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)
Education & Training
- FellowUniversity of Chicago (1984)
- ResidencyTemple University Hospital (1982)
- MDJefferson Medical College (1979)
- BSPennsylvania State University (1977)
Additional Information
- AB of Internal Medicine, Endocrinology & Metabolism (1985)
- AB of Internal Medicine, Internal Medicine (1982)
- Sims E, Russell W, Cuthbertson D, Skyler J, Jacobsen L, Ismail H, Redondo M, Nathan B, Carr A, Taylor P, Dayan C, Galderisi A, Herold K, Sosenko J. Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes 2025 PMID: 40877213, DOI: 10.2337/db25-0310.
- Quandt Z, Young A, Barlow G, Smith J, Kusmartseva I, Dong S, Shapiro M, Kang J, Felton J, Nguyen V, Szot G, Hassoun A, Perdigoto A, Herold K, Nolan G, Bollyky P, Brusko T, Nakayama M, Cooper S, Anderson M. Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal For ImmunoTherapy Of Cancer 2025, 13: e011818. PMID: 40813111, PMCID: PMC12359507, DOI: 10.1136/jitc-2025-011818.
- Dai Y, Aizenbud L, Qin K, Austin M, Jaycox J, Cunningham J, Wang E, Zhang L, Fischer S, Carroll S, van Aggelen H, Kluger Y, Herold K, Furchtgott L, Kluger H, Ring A. Humoral determinants of checkpoint immunotherapy. Nature 2025, 644: 527-536. PMID: 40702172, DOI: 10.1038/s41586-025-09188-4.
- Sydney G, Wu S, Herold K. Moving the Goalposts Closer: Using Intermediate End Points in Type 1 Diabetes Prevention Trials. Diabetes Care 2025, 48: 1318-1319. PMID: 40690655, PMCID: PMC12279035, DOI: 10.2337/dci25-0041.
- ISMAIL H, CUTHBERTSON D, NATHAN B, SOSENKO J, HEROLD K, SIMS E, LIBMAN I, REDONDO M, SPEAKE C. 1523-P: Risk Profiles and Characteristics of Relatives of People with Type 1 Diabetes (T1D) with Single Autoantibody (SAB) Reversion. Diabetes 2025, 74 DOI: 10.2337/db25-1523-p.
- CARR A, GALDERISI A, TAYLOR P, BONET J, CUTHBERTSON D, SOSENKO J, SIMS E, EVANS-MOLINA C, DALLA MAN C, SENIOR P, ISMAIL H, NATHAN B, PETRELLI A, SHERR J, HEROLD K, RUSSELL W, MORAN A, DAYAN C. 1962-LB: Baseline Insulin Secretion Determines the Response to Abatacept In Stage 1 Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1962-lb.
- Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long S, McNamara J, Nguyen H, Serti E, Sumida T, Herold K. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. Nature Communications 2025, 16: 5033. PMID: 40447640, PMCID: PMC12125364, DOI: 10.1038/s41467-025-60276-5.
- Herold K, Dayan C, Kordonouri O, Chatenoud L, Gitelman S, Šumník Z, Simmons K, Szypowska A, Knecht L, Niemoeller E, Tian W, Ramos E. PROTECT Per-Protocol-Analyse: Erhaltung der β-Zellfunktion bei Kindern und Jugendlichen mit neu diagnostiziertem Typ-1-Diabetes Stadium 3. Diabetologie Und Stoffwechsel 2025, 20: s40-s41. DOI: 10.1055/s-0045-1807433.
- Dayan C, Herold K, Simmons K, Šumník Z, Knecht L, Popescu L, Tian W, Gonzalez O, Kordonouri O, Niemoeller E, Gitelman S. Sicherheit von Teplizumab bei Typ-1-Diabetes im Stadium 2 und Stadium 3: Integrierte Analyse klinischer Studien. Diabetologie Und Stoffwechsel 2025, 20: s55-s55. DOI: 10.1055/s-0045-1807462.
- Quandt Z, Lucas A, Liang S, Yang E, Stone S, Fadlullah M, Bayless N, Marr S, Thompson M, Padron L, Bucktrout S, Butterfield L, Tan A, Herold K, Bluestone J, Anderson M, Spencer C, Young A, Connolly J. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. Journal For ImmunoTherapy Of Cancer 2025, 13: e011545. PMID: 40355283, PMCID: PMC12083316, DOI: 10.1136/jitc-2025-011545.
- Jacobsen L, Felton J, Nathan B, Speake C, Krischer J, Herold K. Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding. Diabetes Care 2025, 48: 1112-1124. PMID: 40272284, PMCID: PMC12178618, DOI: 10.2337/dc24-2908.
- Sosenko J, Cuthbertson D, Jacobsen L, Redondo M, Sims E, Ismail H, Herold K, Skyler J, Nathan B, Groups D. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics 2025, 27: 179-186. PMID: 39757867, PMCID: PMC12084817, DOI: 10.1089/dia.2024.0422.
- Redondo M, Cuthbertson D, Steck A, Herold K, Oram R, Atkinson M, Brusko T, Parikh H, Krischer J, Onengut-Gumuscu S, Rich S, Sosenko J. Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes. Diabetologia 2024, 68: 588-601. PMID: 39670998, PMCID: PMC11832693, DOI: 10.1007/s00125-024-06338-7.
- Genosar R, Coman M, Herold K. Reversing Diabetes With Your Own Cells: Closer to the Dream. The Journal Of Clinical Endocrinology & Metabolism 2024, dgae851. PMID: 39673177, DOI: 10.1210/clinem/dgae851.
- Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, Ismail H, Herold K, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia 2024, 68: 646-661. PMID: 39560746, PMCID: PMC11832608, DOI: 10.1007/s00125-024-06323-0.
- Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.
- Greenbaum C, Nepom G, Wood-Heickman L, Wherrett D, DiMeglio L, Herold K, Krischer J. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes 2024, 73: 1780-1790. PMID: 39167668, PMCID: PMC11493760, DOI: 10.2337/dbi24-0020.
- Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley P, Long S, Liu C, Koroleva G, Martins A, Tsang J, Herold K. Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes. Journal Of Clinical Investigation 2024, 134: e177492. PMID: 39137044, PMCID: PMC11405034, DOI: 10.1172/jci177492.
- Quandt Z, Perdigoto A, Anderson M, Herold K. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives In Medicine 2024, 15: a041603. PMID: 39038853, PMCID: PMC11917379, DOI: 10.1101/cshperspect.a041603.
- REDONDO M, BUNDY B, PARIKH H, YOU L, TRIOLO T, FERRAT L, TEMPLEMAN E, TOSUR M, STECK A, GOTTLIEB P, ONENGUT-GUMUSCU S, RICH S, ORAM R, HEROLD K, KRISCHER J. 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention. Diabetes 2024, 73 DOI: 10.2337/db24-68-or.
- MICHALEK D, ONENGUT-GUMUSCU S, CHEN W, BRUSKO T, STECK A, GOTTLIEB P, ORAM R, KRISCHER J, PARIKH H, REDONDO M, HEROLD K, RICH S. 155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab). Diabetes 2024, 73 DOI: 10.2337/db24-155-or.
- HEROLD K, DAYAN C, CHATENOUD L, GITELMAN S, SUMNIK Z, SIMMONS K, SZYPOWSKA A, KNECHT L, NIEMOELLER E, TIAN W, RAMOS E. 70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D). Diabetes 2024, 73 DOI: 10.2337/db24-70-or.
- GITELMAN S, HEROLD K, SIMMONS K, SUMNIK Z, KNECHT L, NIEMOELLER E, TIAN W, COMER G, MILLER D, RAMOS E. 728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic. Diabetes 2024, 73 DOI: 10.2337/db24-728-p.
- Bender C, Wiedeman A, Hu A, Ylescupidez A, Sietsema W, Herold K, Griffin K, Gitelman S, Long S, Gottlieb P, Strock R, Chesshir L, Redondo M, Williams C, Clements M, Moore W, DiMeglio L, Legge M, Mullen M, Sanchez J, Spall M, Woerner S, Gaglia J, Resnick B, Bryant N, Krishfield S, Turley J, Koshy N, Mackey M, Guttmann-Bauman I, Fitch R, Bartholow L, Shelso J, Al Nofal A, Hanisch K, Casas L, Thurlow B, Gottschalk M, Hashiguchi M, Paglia L, Lam A, Sanda S, Torok C, Wesch R, Moore D, Russell W, Smith T, Brown A, Brendle F, Haller M, Cintron M, Baidal D, Matheson D, Blaschke C, Moran A, Pappensus E, Leschyshyn J, Street A. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Science Translational Medicine 2024, 16: eadn2404. PMID: 38718135, DOI: 10.1126/scitranslmed.adn2404.
- lledo delgado A, Preston-Hurlburt P, Currie S, Clark P, Herold K. Reshaping immune cells and the antigen-specific repertoire by anti-CD3 mAb teplizumab in Type 1 diabetes. The Journal Of Immunology 2024, 212: 0958_5059-0958_5059. DOI: 10.4049/jimmunol.212.supp.0958.5059.
- Wu Y, Spurrell M, Deng S, Herold K. Single-cell transcriptomics of CD8 T cells in autoimmune diabetes after anti-CD3 monoclonal antibody treatment. The Journal Of Immunology 2024, 212: 0998_4625-0998_4625. DOI: 10.4049/jimmunol.212.supp.0998.4625.
- Herold K, Šumník Z, Kordonouri O, Simmons K, Szypowska A, Dayan C, Chatenoud L, Gitelman S, Knecht L, Niemoeller E, Westerbacka J, Tian W, Ramos E. Teplizumab bei Kindern mit neu diagnostiziertem Typ-1-Diabetes: Ergebnisse der Phase-3-Studie PROTECT. Diabetologie Und Stoffwechsel 2024, 19: s8-s9. DOI: 10.1055/s-0044-1785244.
- Jacobsen L, Cuthbertson D, Bundy B, Atkinson M, Moore W, Haller M, Russell W, Gitelman S, Herold K, Redondo M, Sims E, Wherrett D, Moran A, Pugliese A, Gottlieb P, Sosenko J, Ismail H. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care 2024, 47: 1048-1055. PMID: 38621411, PMCID: PMC11294635, DOI: 10.2337/dc24-0171.
- Latres E, Greenbaum C, Oyaski M, Dayan C, Colhoun H, Lachin J, Skyler J, Rickels M, Ahmed S, Dutta S, Herold K, Marinac M. Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes 2024, 73: 823-833. PMID: 38349844, DOI: 10.2337/dbi23-0012.
- Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.
- Abdel-Karim T, Hodges J, Herold K, Pruett T, Ramanathan K, Hering B, Dunn T, Kirchner V, Beilman G, Bellin M. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International 2024, 37: 12320. PMID: 38357216, PMCID: PMC10864605, DOI: 10.3389/ti.2024.12320.
- Sims E, Cuthbertson D, Jacobsen L, Ismail H, Nathan B, Herold K, Redondo M, Sosenko J. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. The Journal Of Clinical Endocrinology & Metabolism 2024, 109: 2116-2123. PMID: 38267821, PMCID: PMC11244203, DOI: 10.1210/clinem/dgae048.
- Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A, Gitelman S, Knecht L, Niemoeller E, Tian W, Herold K. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal Of Medicine 2023, 389: 2151-2161. PMID: 37861217, DOI: 10.1056/nejmoa2308743.
- Libman I, Bingley P, Becker D, Buckner J, DiMeglio L, Gitelman S, Greenbaum C, Haller M, Ismail H, Krischer J, Moore W, Moran A, Muir A, Raman V, Steck A, Toledo F, Wentworth J, Wherrett D, White P, You L, Herold K, Steck A, Greenbaum C, Lord S, Monzavi R, Katz L, Goland R, Muir A, Apperson E, DiMeglio L, Cummings E, Weinstock R, Gaglia J, Campbell F, Cabrera S, Nakhle S, English P, Huynh T, Liljenquist D, Moudiotis C, Duke S, Bosi E, Griffin K, Borg H, Lernmark A, Flynn D, Wilson D, Craig M, Moore W, Wherrett D, Tatovich D, Gitelman S, Philipson L, Haller M, Knip M, Tsalikian E, Baidal D, Thomas I, Moran A, Libman I, White P, Raman V, Raleigh Z, Solorzano C, Rodriguez H, Russell W, So M, Colman P, Couper J, Sherr J. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023, 46: 2035-2043. PMID: 37708415, PMCID: PMC10620539, DOI: 10.2337/dc23-1096.
- Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ, Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A, Keller MJ, Herold KC, Herold BC. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine 2020, 12: eabd5487. PMID: 32958614, PMCID: PMC7658796, DOI: 10.1126/scitranslmed.abd5487.
- Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.
- Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.
- Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP. β Cell death and dysfunction during type 1 diabetes development in at-risk individuals. Journal Of Clinical Investigation 2015, 125: 1163-1173. PMID: 25642774, PMCID: PMC4362259, DOI: 10.1172/jci78142.
- Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Science Translational Medicine 2012, 4: 118ra12. PMID: 22277969, PMCID: PMC4131554, DOI: 10.1126/scitranslmed.3003401.
- Yale EndocrinologyDana Clinic Building789 Howard Avenue, Fl 2ndNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
Biography
Kevan Herold, MD, is an endocrinologist who treats adult and child patients with type 1 and type 2 diabetes, diabetes that occurs after therapies for cancer, and hypoglycemia (low blood glucose levels).
Type 1 diabetes is an autoimmune disease that is often diagnosed in children and teens. The immune system mistakenly attacks healthy body tissues and destroys cells in the pancreas that produce insulin.
Dr. Herold’s goal is to better understand the mechanisms for type 1 diabetes in order to develop new treatments for his patients. His research revolves around beta cell function. In type 1 diabetes, beta cells produce little or no insulin and are destroyed by T cells from the immune system. Dr. Herold and his lab also research autoimmune diabetes development in cancer patients.
Recently, Dr. Herold was the principal investigator for a clinical trial that showed the effectiveness of teplizumab, a new drug that could delay type 1 diabetes development by two years. He is chair of NIDDK (National Institute of Diabetes and Digestive Diseases) TrialNet, an international network of type 1 diabetes researchers.
Dr. Herold is C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology) at Yale School of Medicine.
Titles
- C.N.H. Long Professor of Immunobiology and of Medicine (Endocrinology)
Education & Training
- FellowUniversity of Chicago (1984)
- ResidencyTemple University Hospital (1982)
- MDJefferson Medical College (1979)
- BSPennsylvania State University (1977)
Additional Information
- AB of Internal Medicine, Endocrinology & Metabolism (1985)
- AB of Internal Medicine, Internal Medicine (1982)
- Sims E, Russell W, Cuthbertson D, Skyler J, Jacobsen L, Ismail H, Redondo M, Nathan B, Carr A, Taylor P, Dayan C, Galderisi A, Herold K, Sosenko J. Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes 2025 PMID: 40877213, DOI: 10.2337/db25-0310.
- Quandt Z, Young A, Barlow G, Smith J, Kusmartseva I, Dong S, Shapiro M, Kang J, Felton J, Nguyen V, Szot G, Hassoun A, Perdigoto A, Herold K, Nolan G, Bollyky P, Brusko T, Nakayama M, Cooper S, Anderson M. Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas. Journal For ImmunoTherapy Of Cancer 2025, 13: e011818. PMID: 40813111, PMCID: PMC12359507, DOI: 10.1136/jitc-2025-011818.
- Dai Y, Aizenbud L, Qin K, Austin M, Jaycox J, Cunningham J, Wang E, Zhang L, Fischer S, Carroll S, van Aggelen H, Kluger Y, Herold K, Furchtgott L, Kluger H, Ring A. Humoral determinants of checkpoint immunotherapy. Nature 2025, 644: 527-536. PMID: 40702172, DOI: 10.1038/s41586-025-09188-4.
- Sydney G, Wu S, Herold K. Moving the Goalposts Closer: Using Intermediate End Points in Type 1 Diabetes Prevention Trials. Diabetes Care 2025, 48: 1318-1319. PMID: 40690655, PMCID: PMC12279035, DOI: 10.2337/dci25-0041.
- ISMAIL H, CUTHBERTSON D, NATHAN B, SOSENKO J, HEROLD K, SIMS E, LIBMAN I, REDONDO M, SPEAKE C. 1523-P: Risk Profiles and Characteristics of Relatives of People with Type 1 Diabetes (T1D) with Single Autoantibody (SAB) Reversion. Diabetes 2025, 74 DOI: 10.2337/db25-1523-p.
- CARR A, GALDERISI A, TAYLOR P, BONET J, CUTHBERTSON D, SOSENKO J, SIMS E, EVANS-MOLINA C, DALLA MAN C, SENIOR P, ISMAIL H, NATHAN B, PETRELLI A, SHERR J, HEROLD K, RUSSELL W, MORAN A, DAYAN C. 1962-LB: Baseline Insulin Secretion Determines the Response to Abatacept In Stage 1 Type 1 Diabetes. Diabetes 2025, 74 DOI: 10.2337/db25-1962-lb.
- Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long S, McNamara J, Nguyen H, Serti E, Sumida T, Herold K. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. Nature Communications 2025, 16: 5033. PMID: 40447640, PMCID: PMC12125364, DOI: 10.1038/s41467-025-60276-5.
- Herold K, Dayan C, Kordonouri O, Chatenoud L, Gitelman S, Šumník Z, Simmons K, Szypowska A, Knecht L, Niemoeller E, Tian W, Ramos E. PROTECT Per-Protocol-Analyse: Erhaltung der β-Zellfunktion bei Kindern und Jugendlichen mit neu diagnostiziertem Typ-1-Diabetes Stadium 3. Diabetologie Und Stoffwechsel 2025, 20: s40-s41. DOI: 10.1055/s-0045-1807433.
- Dayan C, Herold K, Simmons K, Šumník Z, Knecht L, Popescu L, Tian W, Gonzalez O, Kordonouri O, Niemoeller E, Gitelman S. Sicherheit von Teplizumab bei Typ-1-Diabetes im Stadium 2 und Stadium 3: Integrierte Analyse klinischer Studien. Diabetologie Und Stoffwechsel 2025, 20: s55-s55. DOI: 10.1055/s-0045-1807462.
- Quandt Z, Lucas A, Liang S, Yang E, Stone S, Fadlullah M, Bayless N, Marr S, Thompson M, Padron L, Bucktrout S, Butterfield L, Tan A, Herold K, Bluestone J, Anderson M, Spencer C, Young A, Connolly J. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. Journal For ImmunoTherapy Of Cancer 2025, 13: e011545. PMID: 40355283, PMCID: PMC12083316, DOI: 10.1136/jitc-2025-011545.
- Jacobsen L, Felton J, Nathan B, Speake C, Krischer J, Herold K. Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding. Diabetes Care 2025, 48: 1112-1124. PMID: 40272284, PMCID: PMC12178618, DOI: 10.2337/dc24-2908.
- Sosenko J, Cuthbertson D, Jacobsen L, Redondo M, Sims E, Ismail H, Herold K, Skyler J, Nathan B, Groups D. A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts. Diabetes Technology & Therapeutics 2025, 27: 179-186. PMID: 39757867, PMCID: PMC12084817, DOI: 10.1089/dia.2024.0422.
- Redondo M, Cuthbertson D, Steck A, Herold K, Oram R, Atkinson M, Brusko T, Parikh H, Krischer J, Onengut-Gumuscu S, Rich S, Sosenko J. Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes. Diabetologia 2024, 68: 588-601. PMID: 39670998, PMCID: PMC11832693, DOI: 10.1007/s00125-024-06338-7.
- Genosar R, Coman M, Herold K. Reversing Diabetes With Your Own Cells: Closer to the Dream. The Journal Of Clinical Endocrinology & Metabolism 2024, dgae851. PMID: 39673177, DOI: 10.1210/clinem/dgae851.
- Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, Ismail H, Herold K, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia 2024, 68: 646-661. PMID: 39560746, PMCID: PMC11832608, DOI: 10.1007/s00125-024-06323-0.
- Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.
- Greenbaum C, Nepom G, Wood-Heickman L, Wherrett D, DiMeglio L, Herold K, Krischer J. Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop. Diabetes 2024, 73: 1780-1790. PMID: 39167668, PMCID: PMC11493760, DOI: 10.2337/dbi24-0020.
- Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley P, Long S, Liu C, Koroleva G, Martins A, Tsang J, Herold K. Teplizumab induces persistent changes in the antigen‐specific repertoire in individuals at‐risk for type 1 diabetes. Journal Of Clinical Investigation 2024, 134: e177492. PMID: 39137044, PMCID: PMC11405034, DOI: 10.1172/jci177492.
- Quandt Z, Perdigoto A, Anderson M, Herold K. Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory Disease. Cold Spring Harbor Perspectives In Medicine 2024, 15: a041603. PMID: 39038853, PMCID: PMC11917379, DOI: 10.1101/cshperspect.a041603.
- REDONDO M, BUNDY B, PARIKH H, YOU L, TRIOLO T, FERRAT L, TEMPLEMAN E, TOSUR M, STECK A, GOTTLIEB P, ONENGUT-GUMUSCU S, RICH S, ORAM R, HEROLD K, KRISCHER J. 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention. Diabetes 2024, 73 DOI: 10.2337/db24-68-or.
- MICHALEK D, ONENGUT-GUMUSCU S, CHEN W, BRUSKO T, STECK A, GOTTLIEB P, ORAM R, KRISCHER J, PARIKH H, REDONDO M, HEROLD K, RICH S. 155-OR: Genetic Variation and Time to Progression in TN10 (Teplizumab). Diabetes 2024, 73 DOI: 10.2337/db24-155-or.
- HEROLD K, DAYAN C, CHATENOUD L, GITELMAN S, SUMNIK Z, SIMMONS K, SZYPOWSKA A, KNECHT L, NIEMOELLER E, TIAN W, RAMOS E. 70-OR: PROTECT Per-Protocol Analysis—Preserving ß-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D). Diabetes 2024, 73 DOI: 10.2337/db24-70-or.
- GITELMAN S, HEROLD K, SIMMONS K, SUMNIK Z, KNECHT L, NIEMOELLER E, TIAN W, COMER G, MILLER D, RAMOS E. 728-P: Experience with Teplizumab in the PROTECT Type 1 Diabetes (T1D) Study during the COVID-19 Pandemic. Diabetes 2024, 73 DOI: 10.2337/db24-728-p.
- Bender C, Wiedeman A, Hu A, Ylescupidez A, Sietsema W, Herold K, Griffin K, Gitelman S, Long S, Gottlieb P, Strock R, Chesshir L, Redondo M, Williams C, Clements M, Moore W, DiMeglio L, Legge M, Mullen M, Sanchez J, Spall M, Woerner S, Gaglia J, Resnick B, Bryant N, Krishfield S, Turley J, Koshy N, Mackey M, Guttmann-Bauman I, Fitch R, Bartholow L, Shelso J, Al Nofal A, Hanisch K, Casas L, Thurlow B, Gottschalk M, Hashiguchi M, Paglia L, Lam A, Sanda S, Torok C, Wesch R, Moore D, Russell W, Smith T, Brown A, Brendle F, Haller M, Cintron M, Baidal D, Matheson D, Blaschke C, Moran A, Pappensus E, Leschyshyn J, Street A. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Science Translational Medicine 2024, 16: eadn2404. PMID: 38718135, DOI: 10.1126/scitranslmed.adn2404.
- lledo delgado A, Preston-Hurlburt P, Currie S, Clark P, Herold K. Reshaping immune cells and the antigen-specific repertoire by anti-CD3 mAb teplizumab in Type 1 diabetes. The Journal Of Immunology 2024, 212: 0958_5059-0958_5059. DOI: 10.4049/jimmunol.212.supp.0958.5059.
- Wu Y, Spurrell M, Deng S, Herold K. Single-cell transcriptomics of CD8 T cells in autoimmune diabetes after anti-CD3 monoclonal antibody treatment. The Journal Of Immunology 2024, 212: 0998_4625-0998_4625. DOI: 10.4049/jimmunol.212.supp.0998.4625.
- Herold K, Šumník Z, Kordonouri O, Simmons K, Szypowska A, Dayan C, Chatenoud L, Gitelman S, Knecht L, Niemoeller E, Westerbacka J, Tian W, Ramos E. Teplizumab bei Kindern mit neu diagnostiziertem Typ-1-Diabetes: Ergebnisse der Phase-3-Studie PROTECT. Diabetologie Und Stoffwechsel 2024, 19: s8-s9. DOI: 10.1055/s-0044-1785244.
- Jacobsen L, Cuthbertson D, Bundy B, Atkinson M, Moore W, Haller M, Russell W, Gitelman S, Herold K, Redondo M, Sims E, Wherrett D, Moran A, Pugliese A, Gottlieb P, Sosenko J, Ismail H. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care 2024, 47: 1048-1055. PMID: 38621411, PMCID: PMC11294635, DOI: 10.2337/dc24-0171.
- Latres E, Greenbaum C, Oyaski M, Dayan C, Colhoun H, Lachin J, Skyler J, Rickels M, Ahmed S, Dutta S, Herold K, Marinac M. Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. Diabetes 2024, 73: 823-833. PMID: 38349844, DOI: 10.2337/dbi23-0012.
- Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.
- Abdel-Karim T, Hodges J, Herold K, Pruett T, Ramanathan K, Hering B, Dunn T, Kirchner V, Beilman G, Bellin M. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International 2024, 37: 12320. PMID: 38357216, PMCID: PMC10864605, DOI: 10.3389/ti.2024.12320.
- Sims E, Cuthbertson D, Jacobsen L, Ismail H, Nathan B, Herold K, Redondo M, Sosenko J. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. The Journal Of Clinical Endocrinology & Metabolism 2024, 109: 2116-2123. PMID: 38267821, PMCID: PMC11244203, DOI: 10.1210/clinem/dgae048.
- Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A, Gitelman S, Knecht L, Niemoeller E, Tian W, Herold K. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal Of Medicine 2023, 389: 2151-2161. PMID: 37861217, DOI: 10.1056/nejmoa2308743.
- Libman I, Bingley P, Becker D, Buckner J, DiMeglio L, Gitelman S, Greenbaum C, Haller M, Ismail H, Krischer J, Moore W, Moran A, Muir A, Raman V, Steck A, Toledo F, Wentworth J, Wherrett D, White P, You L, Herold K, Steck A, Greenbaum C, Lord S, Monzavi R, Katz L, Goland R, Muir A, Apperson E, DiMeglio L, Cummings E, Weinstock R, Gaglia J, Campbell F, Cabrera S, Nakhle S, English P, Huynh T, Liljenquist D, Moudiotis C, Duke S, Bosi E, Griffin K, Borg H, Lernmark A, Flynn D, Wilson D, Craig M, Moore W, Wherrett D, Tatovich D, Gitelman S, Philipson L, Haller M, Knip M, Tsalikian E, Baidal D, Thomas I, Moran A, Libman I, White P, Raman V, Raleigh Z, Solorzano C, Rodriguez H, Russell W, So M, Colman P, Couper J, Sherr J. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023, 46: 2035-2043. PMID: 37708415, PMCID: PMC10620539, DOI: 10.2337/dc23-1096.
- Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, Garforth SJ, Herrera NG, Jangra RK, Morano NC, Orner E, Sy S, Chandran K, Dziura J, Almo SC, Ring A, Keller MJ, Herold KC, Herold BC. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Science Translational Medicine 2020, 12: eabd5487. PMID: 32958614, PMCID: PMC7658796, DOI: 10.1126/scitranslmed.abd5487.
- Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal Of Medicine 2019, 381: 603-613. PMID: 31180194, PMCID: PMC6776880, DOI: 10.1056/nejmoa1902226.
- Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.
- Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP. β Cell death and dysfunction during type 1 diabetes development in at-risk individuals. Journal Of Clinical Investigation 2015, 125: 1163-1173. PMID: 25642774, PMCID: PMC4362259, DOI: 10.1172/jci78142.
- Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R, Herold KC. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Science Translational Medicine 2012, 4: 118ra12. PMID: 22277969, PMCID: PMC4131554, DOI: 10.1126/scitranslmed.3003401.
- Yale EndocrinologyDana Clinic Building789 Howard Avenue, Fl 2ndNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510
- Yale EndocrinologyDana Clinic Building789 Howard Avenue, Fl 2ndNew Haven, CT 06519
- Yale Endocrinology & MetabolismYale New Haven Hospital20 York StreetNew Haven, CT 06510